Massimo Di Maio, Associate Professor of Medical Oncology at Department of Oncology, University of Turin, shared a post on X:
“Subsequent treatments received after progression are integral part of the patients’ clinical management, NOT a confounding factor for the real impact of experimental therapy. In my opinion, overall survival analysis should NOT be adjusted for subsequent treatments.”
More posts featuring Massimo Di Maio on OncoDaily.